COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG

WIPO Patent Application WO/2023/095860

A1

The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substituted aromatic heterocyclic group; R2 represents an optionally substituted 6-membered aromatic carbon ring group; R3 represents an optionally substituted aromatic heterocyclic group; -X- is -NH-; m is 0 or 1; R5a represents a hydrogen atom; R5b represents a hydrogen atom; n is 1; R4a represents a hydrogen atom; and R4b represents a hydrogen atom) or a pharmaceutically acceptable salt thereof; and (B) a COVID-19 aggravation inhibitor.

WO/2003/062149	ANTIMICROBIAL COMPOSITION INCLUDING A TRIAMINE AND A BIOCIDE
WO/2023/222055	DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF
JP2011173890	HETEROCYCLIC INHIBITOR OF MEK AND METHOD OF USE THEREOF

YANO RYUICHI (JP)
YAMAMOTO ATSUKO (JP)
NOBORI HARUAKI (JP)
KATO TERUHISA (JP)

PCT/JP2022/043490

June 01, 2023

November 25, 2022

Click for automatic bibliography generation  

SHIONOGI & CO (JP)

A61K31/53; A61K31/235; A61K31/403; A61K31/404; A61K31/661; A61K31/7068; A61K31/7076; A61K39/395; A61K45/00; A61P31/14; A61P43/00; C07D401/14; C07D403/12; C07D417/12

WO2022138988A1	2022-06-30
WO2021250648A1	2021-12-16
WO2010092966A1	2010-08-19
WO2012020749A1	2012-02-16
WO2014200078A1	2014-12-18
WO2021205298A1	2021-10-14

AKAJI KENICHI, KONNO HIROYUKI: "Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease", MOLECULES, vol. 25, no. 17, pages 3920, XP055826867, DOI: 10.3390/molecules25173920

SUGITA Ken-ichi et al. (JP)

View/Download PDF      PDF Help

Previous Patent: CAN LID FOR FOOD OR DRINK

Next Patent: FLEXURAL STRUCTURE AND HALF-FINISHED PRODUCT THEREOF